Schering Intron A/Rebetol Treatment-Naive Hepatitis C Data Close To Filing
Executive Summary
Data from naive chronic hepatitis C patients treated with Schering-Plough's Intron A/Rebetol combination therapy are being analyzed, Schering Hepatology Clinical Director Janice Albrecht, MD, told FDA's Antiviral Drugs Advisory Committee May 4.
You may also be interested in...
Bristol Seeking Two NDAs For UFT Combos In Response To Rebetron Debate
Bristol-Myers Squibb's submission of two separate NDAs for the combination use of UFT and leucovorin appears to be a new filing and approval strategy for the development of bundled multi-ingredient products.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011